Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to tr… Read more
Palvella Therapeutics, Inc (PVLA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.204x
Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) has a cash flow conversion efficiency ratio of -0.204x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.88 Million) by net assets ($38.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Palvella Therapeutics, Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Palvella Therapeutics, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Palvella Therapeutics, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palvella Therapeutics, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hubei DOTI Micro Technology Co. Ltd.
SHE:301183
|
0.036x |
|
Horizon Bancorp
NASDAQ:HBNC
|
0.016x |
|
UNIVEST FINL CORP. DL 5
F:UVE
|
N/A |
|
Bank Ina Perdana PT
JK:BINA
|
-0.047x |
|
Ufuk Yatirim Yonetim Ve Gayrimenkul AS
IS:UFUK
|
-0.002x |
|
Zhejiang Supor Co Ltd
SHE:002032
|
0.153x |
|
KMDHF
PINK:KMDHF
|
0.091x |
|
Golden Ocean Group Ltd
NASDAQ:GOGL
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Palvella Therapeutics, Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Palvella Therapeutics, Inc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $62.61 Million | $-10.84 Million | -0.173x | -104.90% |
| 2023-12-31 | $-3.88 Million | $-13.70 Million | 3.532x | +451.51% |
| 2022-12-31 | $-23.17 Million | $-14.84 Million | 0.640x | +524.31% |
| 2021-12-31 | $50.76 Million | $-7.66 Million | -0.151x | +89.80% |
| 2020-12-31 | $31.03 Million | $-45.90 Million | -1.479x | -- |